Prevention of Weight Gain in Early Psychoses

• ClinicalTrials.gov Identifier: NCT01075295
• Recruitment Status: Completed
• First Posted: February 25, 2010
• Last Update Posted: July 25, 2017
• Sponsor: Centre for Addiction and Mental Health
• Collaborator: Canadian Institutes of Health Research (CIHR)
• Information provided by (Responsible Party): Rohan Ganguli, Centre for Addiction and Mental Health

Study Description

Brief Summary:

The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major Depressive Disorder With Psychotic Features,Substance-Induced Psychoses,Psychosis Not-Otherwise-Specified (NOS)randomly assigned to a stepped behavioral intervention for the prevention of weight gain will experience less weight gain than individuals who receive usual care. There are several studies that have examined the effect of pharmacological and non-pharmacological behavioural approaches for weight loss in patients with psychosis, however studies examining strategies for prevention of obesity are lacking. This study is an important and novel approach to studying the problem of obesity in those with psychosis.

Condition or disease	Intervention/treatment	Phase
Schizophreniform Disorder; Bipolar I Disorder; Bipolar II Disorder; Major Depressive Disorder; Substance-Induced Psychoses; Psychosis Not Otherwise Specified; Schizophrenia; Schizoaffective Disorder	Behavioral: Behavioural Intervention for the Prevention of Weight Gain; Other: TAU	Not Applicable

Detailed Description:

The rates of obesity and related co-morbidities are several-fold higher in patients with psychosis than in the general population. In addition the life expectancy 20% shorter. Several lifestyle and illness-related factors have been implicated for these high rates, including weight gain associated with treatment with novel antipsychotics. The most important cause of death in psychosis patients is coronary heart disease (CHD), of which obesity is a major risk factor. As well, diabetes and its associated complications occur at high rates in persons with psychosis, and diabetes is both related to obesity and is an independent risk factor for CVD and mortality. It therefore seems reasonable to assume that prevention of obesity may lead to a reduced risk for CVD and diabetes. If the proposed intervention proves successful in preventing weight gain and reducing risk for CVD and diabetes, the quality and length of life for persons with psychosis will be vastly improved and medical costs reduced.

Specifically, we hypothesize that : 1a) a smaller proportion of those in the intervention will gain weight (2% or more) as compared to those receiving usual care, 1b) the mean weight gain of those randomized to the intervention will be less than the mean weight gain in those randomized to usual care 2) Increases in Body Mass Index (BMI) and waist circumference (WC) will be smaller in the intervention group as compared to the controls. 3) there will be smaller increases in cholesterol, triglycerides, blood glucose and insulin levels in the intervention group than in the control group. Exploratory analyses of changes in makers for systemic inflammation, and their relationship to weight, and lipid changes, will be conducted to develop novel hypotheses regarding mediators of CVD risk in psychosis.

The study will recruit sixty persons or outpatients with DSM-lV Psychosis with a BMI of < 30 kg/m², who have been treated for less than 2 years (Early SZ) and meet the other enrollment criteria. They will be randomly assigned in the allocation ratio 1:1 to either get a stepped behavioural intervention for prevention of weight gain (n=30) or treatment as usual (routine care, n=30). This will be a pragmatic clinical trial of 16-week duration.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 70 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: Prevention of Weight Gain in Early Psychoses
• Study Start Date: February 2010
• Actual Primary Completion Date: December 2012
• Actual Study Completion Date: December 2012

Arms and Interventions

Arm	Intervention/treatment
Experimental: Lifestyle Intervention	Behavioral: Behavioural Intervention for the Prevention of Weight Gain; The intervention consists of four steps: STEP 1 (Watchful Waiting): Measurement of body weight and Waist Circumference at the start (1 visit). Subjects that have a weight gain greater then or equal to 2% of their baseline weight will progress to Step 2; STEP 2 (Self monitoring): Self-monitoring of daily weight, daily food intake & physical activity (1 visit) Subjects that have a weight gain greater then or equal to 2% (from STEP 2) will progress to Step 3; STEP 3 (Nutrition & Exercise Counseling): Counseling for nutrition and physical activity (4 visits; 2 in-clinic, 2 telephone) Subjects that have a weight gain greater then or equal to 2% (from STEP 3) will progress to Step 4; STEP 4 (Intensive): Intensive behavioral training geared towards reducing caloric intake (4 in-clinic visits)
Active Comparator: TAU	Other: TAU; Treatment as provided by individuals' existing healthcare providers

Outcome Measures

Primary Outcome Measures :

1. Weight [ Time Frame: Measured at week 0, 4, 8 and 16 ]
   The proportion with an increase in weight (2% or greater), from baseline to end point.

Secondary Outcome Measures :

1. Laboratory parameters [ Time Frame: Measured at week 0 and 16 ]
   • Fasting glucose
   • Insulin
   • Lipids

Eligibility Criteria

• Ages Eligible for Study: 14 Years to 45 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age between 14 and 45 years (inclusive)
• Male or Female gender
• DSM-IV-TR diagnosis of Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II), Major Depressive Disorder With Psychotic Features, Substance-Induced Psychoses, Psychosis Not-Otherwise-Specified (NOS)
• Outpatient status at the time of randomization
• Duration of antipsychotic treatment of less than 5 years
• Ability to provide informed consent
• Female patients of childbearing potential must be using a medically accepted means of contraception
• Treatment with olanzapine, clozapine, quetiapine,risperidone or paliperidone for less than 8 weeks duration at enrollment
• BMI between 18.5 and 30

Exclusion Criteria:

• Inability to give informed consent
• Currently enrolled in a weight management program
• Currently being treated with a medication to reduce weight
• Patients with unstable or active cardiovascular illnesses (myocardial infarction, congestive heart failure, etc), active or end-stage renal disease, and unstable thyroid disease, etc

Inclusion/exclusion criteria has been intentionally limited in order to maximize the generalizability of the study.

Contacts and Locations

Locations

Canada, Ontario

Centre for Addiction and Mental Health

Toronto, Ontario, Canada, M5T 1R8

Sponsors and Collaborators

Centre for Addiction and Mental Health

Canadian Institutes of Health Research (CIHR)

Investigators

• Principal Investigator: Rohan Ganguli, MD; Centre for Addiction and Mental Health

More Information

Additional Information:

Information about research at the Centre for Addiction and Mental Health, Canada's largest mental health and addiction teaching hospital. It is fully affiliated with the University of Toronto, and is a PAHO/WHO Collaborating Centre. 

• Responsible Party: Rohan Ganguli, M.D., Centre for Addiction and Mental Health
• ClinicalTrials.gov Identifier: NCT01075295
• Other Study ID Numbers: 133/2009
• First Posted: February 25, 2010
• Last Update Posted: July 25, 2017
• Last Verified: July 2017

Keywords provided by Rohan Ganguli, Centre for Addiction and Mental Health:

Schizophreniform Disorder; Schizophrenia, Schizoaffective disorder; Bipolar I Disorder; Bipolar II Disorder; Major Depressive Disorder with Psychotic Features,; Substance-Induced Psychoses; Psychosis Not Otherwise Specified; antipsychotic; weight gain; body mass index; BMI; waist circumference; WC; coronary heart disease; CHD

Additional relevant MeSH terms:

Disease; Weight Gain; Psychoses, Substance-Induced; Schizophrenia; Depressive Disorder; Depression; Depressive Disorder, Major; Psychotic Disorders; Mental Disorders; Shared Paranoid Disorder; Pathologic Processes; Schizophrenia Spectrum and Other Psychotic Disorders; Mood Disorders; Behavioral Symptoms; Body Weight Changes; Body Weight; Poisoning; Chemically-Induced Disorders; Substance-Related Disorders